Literature DB >> 17455362

The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance.

Paul M Young1, Hak-Kim Chan, Herbert Chiou, Stephen Edge, Terence H S Tee, Daniela Traini.   

Abstract

The influence of processing on the performance of carrier material used in dry powder inhalers was investigated. alpha-Lactose monohydrate crystals were processed by ball milling for cumulative time durations and their properties evaluated. As expected, milling reduced the median particle diameter while increasing fine particulate (<10 microm) and amorphous levels. Recrystallization of these partially amorphous samples resulted in a reduction in fines, elimination of amorphous material with little change in median diameter. To study the effects of processing on aerosolization performance, blends of lactose monohydrate with a model drug (nedocromil sodium trihydrate), were evaluated using an in vitro multistage liquid impinger (MSLI) model. In general, milling and storage of the carriers at high humidity (prior to blending) had a significant (ANOVA, p < 0.05) effect on the fine particle fractions (FPF; <6.8 microm). These effects were attributed predominantly to the fines content, showing a strong correlation between increased fines and FPF (R(2) = 0.974 and 0.982 for milled and recrystallized samples, respectively). However, this relationship only existed up to 15% fines concentration, after which agglomerate-carrier segregation was observed and FPF decreased significantly. These results suggest that, after processing, high-dose drug formulation performance is dominated by the presence of fines. (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17455362     DOI: 10.1002/jps.20933

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.

Authors:  Jagdeep Shur; Haggis Harris; Matthew D Jones; J Sebastian Kaerger; Robert Price
Journal:  Pharm Res       Date:  2008-02-01       Impact factor: 4.200

2.  The effect of engineered mannitol-lactose mixture on dry powder inhaler performance.

Authors:  Waseem Kaialy; Hassan Larhrib; Gary P Martin; Ali Nokhodchi
Journal:  Pharm Res       Date:  2012-04-05       Impact factor: 4.200

3.  Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent.

Authors:  Nashwa El-Gendy; Kristin L Aillon; Cory Berkland
Journal:  Int J Pharm       Date:  2010-03-07       Impact factor: 5.875

Review 4.  Physical stability of dry powder inhaler formulations.

Authors:  Nivedita Shetty; David Cipolla; Heejun Park; Qi Tony Zhou
Journal:  Expert Opin Drug Deliv       Date:  2019-12-13       Impact factor: 6.648

5.  Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution.

Authors:  Nashwa El-Gendy; Eric M Gorman; Eric J Munson; Cory Berkland
Journal:  J Pharm Sci       Date:  2009-08       Impact factor: 3.534

6.  Lactose composite carriers for respiratory delivery.

Authors:  Paul M Young; Philip Kwok; Handoko Adi; Hak-Kim Chan; Daniela Traini
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

7.  Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration.

Authors:  Nashwa El-Gendy; Cory Berkland
Journal:  Pharm Res       Date:  2009-05-05       Impact factor: 4.200

8.  Effect of Lactose Pseudopolymorphic Transition on the Aerosolization Performance of Drug/Carrier Mixtures.

Authors:  Andrea Della Bella; Michele Müller; Andrea Danani; Luciano Soldati; Ruggero Bettini
Journal:  Pharmaceutics       Date:  2019-11-04       Impact factor: 6.321

9.  Evidence for the existence of powder sub-populations in micronized materials: aerodynamic size-fractions of aerosolized powders possess distinct physicochemical properties.

Authors:  Sara Jaffari; Ben Forbes; Elizabeth Collins; Jiyi Khoo; Gary P Martin; Darragh Murnane
Journal:  Pharm Res       Date:  2014-12       Impact factor: 4.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.